National Health Commission: China has jumped to second place in global new drug research and development

This morning, the State Council Information Office held a series of themed press conferences on "Successfully Completing the 14th Five-Year Plan," introducing the achievements in health and wellness work during the 14th Five-Year Plan period. It was reported that the number of new drugs under research in China accounts for over 20% of the global total, ranking second in the world for new drug research and development. Several domestically developed innovative drugs, such as Sugliumab, Ensartinib, and Gimatecan, have been successively approved for market launch, filling the gaps in corresponding fields for domestic innovative drugs. The independently developed anti-tumor drug Zebutinib has been approved for market launch in multiple countries